Eton Pharmaceuticals Inc. (ETON)
ETON trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1710340/000143774926009059/0001437749-26-009059-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ETON on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001710340 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $80.0M |
| Net income | -$4.6M |
| Operating income | -$844K |
| Net margin | -5.8% |
| Operating margin | -1.1% |
| Revenue growth | +104.9% |
| Cash | $25.9M |
| Total assets | $92.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 23.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $55.6M cash; operating cash flow $9.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 28,842,215 (2026-11-02); 26,817,535 a year earlier; 25,658,396 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton LLP, Chicago, Illinois, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-06-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $25.2M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $57.9M | $35.2M | $35.2M | $55.6M | $23.1M | $141.1M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $37.6M | $11.6M | $7.3M | $26.8M | $27.9M | $105.6M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $24.3M | $1.6M | $7.4M | $19.7M | $30.7M | $86.9M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $21.3M | $1.5M | -$11.6M | $25.9M | $30.6M | $80.0M | 10-K 2026-03-19 |
| Q3 2025 2025-09-30 | $22.5M | -$1.9M | $12.0M | $37.1M | $30.4M | $70.3M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $18.9M | -$2.6M | $8.0M | $25.4M | $30.2M | $58.2M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $17.3M | -$1.6M | $2.1M | $17.4M | $30.0M | $48.3M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $11.6M | -$598K | -$765K | $14.9M | $29.8M | $39.0M | 10-K 2026-03-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B5 | 424B5 | 2024-12-12 |
| Latest annual report FORM 10-K | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy FORM DEF 14A | DEF 14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 427 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +13.2% |
| 1 month | +19.9% |
| 3 months | +56.7% |
| Year to date | +278.1% |
| 1 year | +278.7% |
| From 52-week high | -6.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ZYME | Zymeworks Inc. | $26.45 | +0.80% | $1.8B |
| AGIO | Agios Pharmaceuticals Inc. | $30.15 | -4.56% | $1.8B |
| ZBIO | Zenas BioPharma Inc. | $27.93 | -0.29% | $1.9B |
| TRVI | Trevi Therapeutics Inc. | $13.29 | -2.64% | $1.9B |
| MRVI | Maravai LifeSciences Holdings Inc. | $7.40 | -1.86% | $1.9B |
| HRMY | Harmony Biosciences Holdings Inc. | $32.96 | -2.37% | $1.9B |
| BRVE | Braveheart Bio Inc. | $19.49 | -0.66% | $1.8B |
| STOK | Stoke Therapeutics Inc. | $26.63 | -0.19% | $1.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier